Medical costs associated with type 2 diabetes complications and comorbidities.

Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Print Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care

Publication: Cranbury, NJ : Clinical Care Targeted Communications Group, LLC
Original Publication: Old Bridge, NJ : American Medical Pub., c1995-

Health Care Costs*/statistics & numerical data ; Health Care Costs*/trends; Diabetes Mellitus, Type 2/*economics; Adolescent ; Adult ; Comorbidity ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Female ; Humans ; Linear Models ; Male ; Medical Audit ; Middle Aged ; United States ; Young Adult

Objectives: To estimate the direct medical costs associated with type 2 diabetes, its complications, and its comorbidities among U.S. managed care patients.
Study Design: Data were from patient surveys, chart reviews, and health insurance claims for 7109 people with type 2 diabetes from 8 health plans participating in the Translating Research Into Action for Diabetes (TRIAD) study between 1999 and 2002.
Methods: A generalized linear regression model was developed to estimate the association of patients' demographic characteristics, tobacco use status, treatments, related complications, and comorbidities with medical costs.
Results: The mean annualized direct medical cost was $2465 for a white man with type 2 diabetes who had been diagnosed fewer than 15 years earlier, was treated with oral medication or diet alone, and had no complications or comorbidities. We found annualized medical costs to be 10% to 50% higher for women and for patients whose diabetes had been diagnosed 15 or more years earlier, who used tobacco, who were being treated with insulin, or who had several other complications. Coronary heart disease, congestive heart failure, hemiplegia, and amputation were each associated with 70% to 150% higher costs. Costs were approximately 300% higher for end-stage renal disease treated with dialysis and approximately 500% higher for end-stage renal disease with kidney transplantation.
Conclusions: Most medical costs incurred by patients with type 2 diabetes are related to complications and comorbidities. Our cost estimates can help when determining the most cost-effective interventions to prevent complications and comorbidities.

Pharmacoeconomics. 1999 Sep;16(3):285-95. (PMID: 10558040)
Diabetes Care. 2004 May;27(5):1047-53. (PMID: 15111519)
Diabetes Care. 2008 Mar;31(3):596-615. (PMID: 18308683)
Diabetes Care. 2003 Mar;26(3):917-32. (PMID: 12610059)
Diabetes Care. 2004 Sep;27(9):2262-5. (PMID: 15333499)
JAMA. 2002 May 15;287(19):2519-27. (PMID: 12020332)
Diabetes Care. 1999 Jul;22(7):1116-24. (PMID: 10388977)
Diabetes Care. 2000 Dec;23(12):1774-9. (PMID: 11128351)
Diabetes Care. 2003 Aug;26(8):2300-4. (PMID: 12882852)
Diabet Med. 2002 Mar;19(3):246-53. (PMID: 11918627)
Diabetes Care. 2002 Feb;25(2):386-9. (PMID: 11815515)
J Intern Med. 2000 Nov;248(5):387-96. (PMID: 11123503)
Diabetes Care. 1998 Sep;21(9):1414-31. (PMID: 9727886)
Med Care. 1996 Jan;34(1):73-84. (PMID: 8551813)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Cardiovasc Diabetol. 2009 Sep 26;8:53. (PMID: 19781099)
BMC Health Serv Res. 2003 Mar 21;3(1):7. (PMID: 12659641)

P30 DK020572 United States DK NIDDK NIH HHS; P30 DK092926 United States DK NIDDK NIH HHS; P60 DK020572 United States DK NIDDK NIH HHS; P60DK020572 United States DK NIDDK NIH HHS

Date Created: 20130621 Date Completed: 20140325 Latest Revision: 20220409

20231215

PMC4337403

23781894